REVANESSE ULTRA
Prollenium Medical Technologies, Inc. · Decision date Aug 4, 2017
What did the FDA approve?
FDA approved PMA P160042 for Revanesse Ultra on August 4, 2017. The approval statement describes the device as an implant for aesthetic use, indicated for injection into the mid to deep dermis to correct moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults 22 years of age or more. The applicant is Prollenium Medical Technologies, Inc., and the product code is LMH.
The record identifies this as an original PMA approval, not a supplement or manufacturing notice. The statement reports the intended use as stated by the applicant; it does not independently establish safety or clinical effectiveness. No supplement type or supplement reason is listed, and the source does not include clinical data, trial information, or comparative performance details.
FDA approval order statement
Approval for the Revanesse Ultra. The device is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults 22 years of age or more.
- Regulatory pathway
- Original PMA
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Aug 4, 2017
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P160042
- Regulatory pathway
- Premarket approval application
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Aug 4, 2017
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
- Product code
- LMH
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P160042 received
Application receipt date recorded by FDA.
P160042 · FDA decision
APPR
P160042/S032 · Related supplement
Revanesse Versa, Revanesse Versa+ (with lidocaine) and Revanesse Lips+ (with lidocaine)
Timeline entries are records held by MedtechLedger for P160042. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160042
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
saypha ChiQP250021/S001 | Croma-Pharma GmbH | PMA supplement | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Prollenium Medical Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 138 Industrial Pkwy. N., Aurora, L4G 4C3
Sources and methodology
- Original FDA record: P160042
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



